Altered mRNA levels of MOV10, A3G, and IFN-α in patients with chronic hepatitis B

Journal of Microbiology

Volumn 52, Issue 6, 2014, Pages 510-514

  Song, Zhi Wei ^a,b   Ma, Yan Xiu ^a   Fu, Bao qing ^a   Teng, Xu ^a   Chen, Si Jia ^a   Xu, Wei Zhen ^a   Gu, Hong Xi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

APOBEC3G; hepatitis B virus; IFN ; innate immune; Moloney Leukemia Virus 10

Indexed keywords

ALPHA INTERFERON; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; MESSENGER RNA; MOV10 PROTEIN, HUMAN; RNA HELICASE; VIRUS DNA;

ADULT; BLOOD; FEMALE; GENETICS; HEPATITIS B; HUMAN; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; VIRUS LOAD;

ADULT; CYTIDINE DEAMINASE; DNA, VIRAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA HELICASES; RNA, MESSENGER; VIRAL LOAD;

EID: 84901602747     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-014-3467-8     Document Type: Article

References (22)

1. Arjan S., Swanson C., Sherer N., and Malim M. 2011. Mov10, an APOBEC3G-interacting RNA-binding protein, inhibits HIV-1 infection. Retrovirology8, 1-1.
2. Bertoletti A. and Ferrari C. 2013. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad. Med. J. 89, 294-304.
3. Bonvin M. and Greeve J. 2008. Hepatitis B: modern concepts in pathogenesis-APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Curr. Opin. Infect. Dis. 21, 298-303.
4. Burdick R., Smith J. L., Chaipan C., Friew Y., Chen J., Venkata chari, N. J., Delviks-Frankenberry K. A., Hu W. S., and Pathak V. K. 2010. P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J. Virol. 84, 10241-10243.
5. Furtak V., Mulky A., Rawlings S. A., Kozhaya L., Lee K., Kewalramani V. N., and Unutmaz D. 2010. Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity. PLoS One5, e9081.
6. Goodier J. L., Cheung L. E., and Kazazian H. H. Jr. 2012. MOV10 RNA helicase is a potent inhibitor of retrotransposition in cells. PLoS Genet. 8, e1002941.
7. Henry M., Guetard D., Suspene R., Rusniok C., Wain-Hobson S., and Vartanian J. P. 2009. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One4, e4227.
8. Lecossier D., Bouchonnet F., Clavel F., and Hance A. J. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science300, 11-2.
9. Lu C. L., Tsai S. T., Chan C. Y., Hwang S. J., Tsai C. Y., Wu J. C., Lu R. H., Lin B. C., and Lee S. D. 1997. Hepatitis B infection and changes in interferon-alpha and-gamma production in patients with systemic lupus erythematosus in Taiwan. J. Gastroenterol. Hepatol. 12, 272-276.
10. Miseta A. 2002. Role of molecular biology investigations in the detection of Hepatitis C virus. Orv. Hetil. 143, 15-7.
11. Mohamadkhani A., Pourdadash A., Tayebi S., Estakhri A., Nazem H., Sotoudeh M., and Poustchi H. 2012. The potential role of APOBEC3G in limiting replication of hepatitis B virus. Arab. J. Gastroenterol. 13, 170-173.
12. Noguchi C., Imamura M., Tsuge M., Hiraga N., Mori N., Miki D., Kimura T., Takahashi S., Fujimoto Y., Ochi H., andet al. 2009. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection. J. Infect. Dis. 199, 1599-1607.
13. Olivero A., Ciancio A., Abate M. L., Gaia S., Smedile A., and Rizzetto M. 2006. Performance of sequence analysis, INNOLiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations. J. Viral. Hepat. 13, 355-362.
14. Peng C., He Y. W., Guo C. X., Zeng L. L., Weng Z. H., and Luo D. D. 2007. Significance of expression of APOBEC3G mRNA in PBMC of chronic hepatitis B patients. Chin. J. Integr. Traditional Western Med. Liver Dis. 5, 5-8.
15. Pollack S. 2002. Chronic fatigue syndrome and immune dysfunction: cause or effect? Isr. Med. Assoc. J. 4, 883-885.
16. Rosler C., Kock J., Kann M., Malim M. H., Blum H. E., Baumert T. F., and von Weizsacker F. 2005. APOBEC-mediated interference with hepadnavirus production. Hepatology42, 301-309.
17. Sheehy A. M., Gaddis N. C., Choi J. D., and Malim M. H. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature418, 646-650.
18. Turelli P., Mangeat B., Jost S., Vianin S., and Trono D. 2004. Inhibition of hepatitis B virus replication by APOBEC3G. Science303, 18-9.
19. Vartanian J. P., Henry M., Marchio A., Suspene R., Aynaud M. M., Guetard D., Cervantes-Gonzalez M., Battiston C., Mazzaferro V., Pineau P., andet al. 2010. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 6, e1000928.
20. Wang X., Han Y., Dang Y., Fu W., Zhou T., Ptak R. G., and Zheng Y. H. 2010. Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus replication. J. Biol. Chem. 285, 14346-14355.
21. Weinbaum C. M., Williams I., Mast E. E., Wang S. A., Finelli L., Wasley A., Neitzel S. M., and Ward J. W. 2008. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 57, 1-20.
22. Zhao D., Wang X., Lou G., Peng G., Li J., Zhu H., Chen F., Li S., Liu D., Chen Z., andet al. 2010. APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems. Virus Res. 151, 213-219.